Valuation check: NPHC's profit margin is -4.67%, below the Healthcare sector average of 15.58%.
Get informed when a big investor buys or sells
+ FollowAs of Mar 2026
Trailing 12 months ending Mar 2026
Nutra Pharma (NPHC) currently reports a profit margin of -4.67% as of March 2026. That compares with -18.99% in the prior-year period — up 75.4% year over year. That is below the Healthcare sector average of 15.58%. Use the charts on this page to explore Nutra Pharma's profit margin history and peer comparisons.
Nutra Pharma's profit margin increased from -18.99% to -4.67% — a 75.4% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Nutra Pharma's profit margin of -4.67% is lower than the Healthcare sector average of 15.58%. That is roughly 3095.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' profit margin, but Nutra Pharma's current -4.67% should be judged against Healthcare norms (sector average: 15.58%) and against NPHC's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current profit margin of -4.67%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 15.58%. From there, open related valuation or income-statement pages for Nutra Pharma, and consider following NPHC for alerts when major investors trade the stock.